Share on StockTwits
 

Intermolecular (NASDAQ:IMI) CEO David E. Lazovsky unloaded 4,552 shares of Intermolecular stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $4.02, for a total transaction of $18,299.04. Following the completion of the transaction, the chief executive officer now directly owns 2,745,638 shares of the company’s stock, valued at approximately $11,037,465. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Intermolecular (NASDAQ:IMI) traded down 8.21% on Friday, hitting $3.69. 386,762 shares of the company’s stock traded hands. Intermolecular has a 1-year low of $3.94 and a 1-year high of $10.69. The stock has a 50-day moving average of $4.54 and a 200-day moving average of $5.53. The company’s market cap is $170.1 million.

Intermolecular (NASDAQ:IMI) last issued its quarterly earnings data on Thursday, February 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $15.57 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. The company’s quarterly revenue was down 10.3% on a year-over-year basis. Analysts expect that Intermolecular will post $-0.11 EPS for the current fiscal year.

IMI has been the subject of a number of recent research reports. Analysts at JPMorgan Chase & Co. cut their price target on shares of Intermolecular from $12.00 to $9.00 in a research note to investors on Friday. Analysts at Needham & Company downgraded shares of Intermolecular from a “buy” rating to a “hold” rating in a research note to investors on Monday, January 6th.

Intermolecular, Inc (NASDAQ:IMI) is engaged in research and development and time-to-market for the semiconductor and clean-energy industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.